Teva Pharmaceutical Industries Ltd (TEVA.N)
27 Mar 2015
(The following statement was released by the rating agency) CHICAGO, March 24 (Fitch) Fitch Ratings has assigned a 'BBB+' rating to the unsecured Euro bond offering issued by Teva Pharmaceutical Finance Netherlands II, B.V. (Israel) part of Teva Pharmaceuticals Industries Ltd. (Teva). Proceeds are expected to be used for general corporate purposes. Fitch does not expect a material change in total debt balances to result as a net effect of this issuance, the February 2015 tender of USD-denom
** IDFC initiates coverage of stock with "outperformer" rating and target price of 2,730 rupees
March 4 - * U.S. judge rules in favor of Teva Pharmaceutical Industries Ltd and
Feb 11 - Israeli drugmaker Teva Pharmaceutical Industries Inc said it found some business practices and transactions could violate the U.S. Foreign Corrupt Practices Act.
* Teva seeks growth markets, complex generics, specialty drugs
* There might not be any generic Copaxone competition in 2015 but we assume there may be -CEO Further company coverage: (Reporting By Steven Scheer)
* Plans 7 drug launches in 2015 with $400 million of new revenue -CEO Further company coverage: (Reporting By Tova Cohen)
TEL AVIV, Feb 5 - Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year.
** India's Cipla rises as much as 4.8 pct to record high of 710 rupees
- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug.